What should change in the validation strategy when raw-material variability increases?

Why

Validation shows a process works with the inputs used during design and PPQ. If those inputs change, the evidence may no longer cover them. The FDA's 2011 guidance includes component inputs in the manufacturing conditions a PPQ protocol must specify, lists incoming raw material records among the signals Stage 3 should watch, and expects changes to process inputs to be evaluated, with further process design and qualification work if quality could be affected.

Annex 15 asks that critical starting material suppliers be qualified before validation batches and that ongoing verification consider incremental changes over time. Imagine a cell culture medium component whose trace metal content now varies more between lots. Earlier, all PPQ lots came from a narrow band.

First, find out whether the variability matters, using development knowledge or small-scale studies that span the new range. If copper levels affect glycosylation, copper becomes a critical material attribute. Options then include tightening the purchase specification, adding incoming testing, adjusting the process within its validated range based on lot data, or showing through new studies that the process is robust to the wider range.

If the range falls outside what PPQ covered, partial revalidation with lots at the extremes may be needed. Meanwhile, Stage 3 monitoring should increase and supplier management should be engaged.